Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Vasculitis
How do you approach management of a young adult after ascending thoracic aneurysm repair with biopsy showing granulomatous inflammation (no other vascular involvement, PET scan normal)?
Rheumatological and infectious work up unrevealing.
Related Questions
How would you approach additional workup and management of a patient with active Crohn’s disease, who has multiple lung and brain nodules, with lung pathology demonstrating necrotizing granulomatous inflammation and brain biopsy with granulomatous inflammation and medium-large vessel vasculitis?
How do you treat IgA cutaneous vasculitis with retiform purpura and evidence of fibrinoid necrosis on skin biopsy?
In a young patient with relapsing polychondritis and aortitis which has led to severe aortic valve regurgitation, is there any preference for a mechanical versus bioprosthetic valve replacement?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
Do you routinely obtain baseline vascular imaging (CTA, MRA, PET) in patients with suspected GCA, but negative temporal artery biopsy?
How would you approach management of incidentally identified unilateral retinal vasculitis with subsequent labs revealing +P-ANCA?
Would you approach a patient with idiopathic bilateral sensorineural hearing loss and episcleritis as atypical Cogan’s syndrome even in the absence of MRI/ MRA changes and minimal elevation of inflammation markers?
Do you recommend PJP prophyalaxis as a rule in giant cell arteritis patients on high dose steroids?
Would you continue Rituximab infusions in a patient with GPA and renal involvement who has been in remission on Avacopan and Rituximab, but had PRES post Rituximab infusion?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?